A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations

See ANZCTR for full trial details >

 

Trial Summary:

To determine whether taking Acetylsalicylic Acid (aspirin) may help to prevent ovarian cancer in women with a high risk gene mutation in BRCA1 or BRCA2, who plan to have the standard risk-reducing surgery.

Supported By:

CCTG with funding from NHMRC

Eligibility:

Women at high risk for getting ovarian cancer who are scheduled, sometime in the next 6 months to 2 years, to have a surgery to reduce the risk of getting ovarian cancer by removing the fallopian tubes and ovaries.

Registration ID:

ACTRN12619000520134

Participation:

Australia, Canada

Australian Lead Group:

ANZGOG

Status:

Recruiting

Activation Date:

9/12/2019

Chairs:

Prof Kelly-Anne Phillips

Contact:

stics.study@sydney.edu.au